A detailed history of Hrt Financial LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Hrt Financial LP holds 27,531 shares of ADCT stock, worth $109,022. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,531
Previous 37,730 27.03%
Holding current value
$109,022
Previous $101,000 8.91%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$2.64 - $4.02 $26,925 - $40,999
-10,199 Reduced 27.03%
27,531 $110,000
Q2 2025

Aug 14, 2025

BUY
$1.1 - $3.67 $41,503 - $138,469
37,730 New
37,730 $101,000
Q4 2024

Feb 14, 2025

BUY
$1.89 - $3.48 $28,487 - $52,454
15,073 New
15,073 $29,000
Q4 2023

Feb 09, 2024

BUY
$0.47 - $1.79 $37,640 - $143,353
80,086 New
80,086 $132,000
Q1 2023

May 12, 2023

BUY
$1.92 - $5.45 $31,361 - $89,020
16,334 New
16,334 $31,000
Q3 2022

Nov 14, 2022

BUY
$4.66 - $10.31 $104,486 - $231,170
22,422 New
22,422 $108,000

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $307M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.